- Home
- RIV vs XOMA Comparison
RIV vs XOMA Comparison
Compare RIV & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIV
- XOMA
- Stock Information
- Founded
- RIV 2015
- XOMA 1981
- Country
- RIV United States
- XOMA United States
- Employees
- RIV N/A
- XOMA N/A
- Industry
- RIV Finance Companies
- XOMA Biotechnology: Pharmaceutical Preparations
- Sector
- RIV Finance
- XOMA Health Care
- Exchange
- RIV Nasdaq
- XOMA Nasdaq
- Market Cap
- RIV 258.1M
- XOMA 300.5M
- IPO Year
- RIV N/A
- XOMA N/A
- Fundamental
- Price
- RIV $12.31
- XOMA $27.70
- Analyst Decision
- RIV
- XOMA Strong Buy
- Analyst Count
- RIV 0
- XOMA 2
- Target Price
- RIV N/A
- XOMA $69.50
- AVG Volume (30 Days)
- RIV 87.6K
- XOMA 71.2K
- Earning Date
- RIV 01-01-0001
- XOMA 08-12-2025
- Dividend Yield
- RIV 12.85%
- XOMA N/A
- EPS Growth
- RIV N/A
- XOMA N/A
- EPS
- RIV N/A
- XOMA N/A
- Revenue
- RIV N/A
- XOMA $42,909,000.00
- Revenue This Year
- RIV N/A
- XOMA $70.91
- Revenue Next Year
- RIV N/A
- XOMA $14.00
- P/E Ratio
- RIV N/A
- XOMA N/A
- Revenue Growth
- RIV N/A
- XOMA 638.41
- 52 Week Low
- RIV $9.63
- XOMA $18.35
- 52 Week High
- RIV $12.43
- XOMA $35.00
- Technical
- Relative Strength Index (RSI)
- RIV 60.22
- XOMA 64.04
- Support Level
- RIV $11.94
- XOMA $23.47
- Resistance Level
- RIV $12.25
- XOMA $28.20
- Average True Range (ATR)
- RIV 0.10
- XOMA 1.26
- MACD
- RIV -0.01
- XOMA 0.29
- Stochastic Oscillator
- RIV 70.97
- XOMA 81.63
About RIV RiverNorth Opportunities Fund Inc.
Rivernorth Opportunities Fund Inc is a diversified, closed-end management investment company. The fund's investment objective is total return consisting of capital appreciation and current income.
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.